BIOSPECTRUM | JUNE 2023 | www.biospectrumindia.com COMPANY NEWS 17



MapMyGenome launches India's first DNA test for personalised skin and hair care

Hyderabad-based MapMyGenome has announced the launch of BeautyMap, a revolutionary DNA-based test that provides personalised recommendations for skin and hair care products based on an individual's unique genetic makeup. The test will be available in the Indian market at a price of Rs 6999. BeautyMap is the first of its kind in India and aims to help people achieve their beauty goals by understanding their genetic predispositions to 40 conditions related to skin and hair care such as acne, hair loss, sun damage, hydration, sleep habits, and vitamin levels, among others. BeautyMap also offers genetic counseling sessions with board-certified genetic counsellors who help individuals interpret their results and make informed decisions about their personalised beauty regimen from the BeautyMap report. The test is simple and non-invasive, requiring only a saliva sample. As part of MapMyGenome's HarGharDna initiative, the test kit will be delivered directly to people's homes. The sample is then analysed in MapMyGenome's state-of-the-art laboratory. The results are delivered to the individual in an easy-to-understand report that includes personalised recommendations for skincare and hair care products through a genetic counselling session.

Murata Vios plans to expand to Middle East, Europe & Japan

Murata Vios, one of leading manufacturers of Remote Monitoring Devices, is planning to expand its operations to the Middle East, Europe and Japan in the next 12-18 months. Currently the company has operations in India and the US. The company is working on formalities of introducing the range of devices/ technologies it has to fulfil the stringent regulatory requirements in the developed markets such as Japan and Europe. With a mission to reduce healthcare facilitation costs, deliver greater clinician productivity, increase operational efficiency, and improve patient outcomes, the company has reached out to 15 hospital partners spread across Tier 1 cities and few Tier II cities such as Bangalore, Mangalore, Hyderabad, Mysore, Pune, Delhi etc. Murata Vios today specialises in medical-grade IoT sensors and remote monitoring services for clients such as hospitals, medical and surgical units, step-down units, specialty care units, long-term acute care hospitals, skilled nursing facilities, and ambulatory surgery centres.

Akums launches novel Combikit for treatment of Duodenal Ulcer and H. pylori infection

New Delhi-based Akums
Drugs and Pharmaceutical has
announced the launch of its
latest formulation, a unique
Combikit — (Amoxicillin +
Clarithromycin + Esomeprazole).
This Combikit is the first of
its kind to be introduced in
India by Akums. Combikit is
approved by the Central Drugs
Standard Control Organisation
(CDSCO) for the healing of
duodenal ulcers associated with

Helicobacter pylori (H. pylori) and the eradication of H. pylori in patients with active or healed peptic ulcer. The H. pylori eradication therapy has shown efficacy in reducing the risk of ulcer recurrence, providing a great benefit for patients. H. pylori is a very common infection in India, implicated in the aetiology of gastritis and peptic ulcers in humans. This Combikit is a combination

of three effective drugs Amoxicillin, Clarithromycin, and
Esomeprazole. This combination
works by inhibiting the growth
of H. pylori bacteria and
reducing the production
of gastric acid. The
drug is available in a
patient-convenient
pack, for a complete
course of therapy.